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Hepatocellular carcinoma (HCC) is a relatively rare tumour
in the USA and Europe, but it is common in much of Asia and
sub-Saharan Africa (Yu and Chen, 1994). There are almost 300
000 000 chronic hepatitis B virus (HBV) carriers in the world,
with the highest prevalence in Southeast Asia, sub-Saharan Africa
and Greenland (Tiollais et al, 1985). Although chronic HBV infec-
tion is the major cause of at least 80% of HCC throughout the
world (Yu and Chen, 1994), only a minority of chronic HBV
carriers are expected to develop HCC in their lifetime (Beasley,
1988). The fact that HCC is not an inevitable consequence of
chronic HBV infection has stimulated the search for other risk
factors. In addition to HBV, many other environmental factors
have been documented as risk factors for HCC, including chronic
infection with hepatitis C virus (HCV), aflatoxin exposure, ciga-
rette smoking, alcohol drinking and low vegetable intake
(Tsukuma et al, 1990; Chen et al, 1991, 1996; Yu et al, 1991; Yu et
al, 1991, 1995b, 1997;Yu and Chen, 1994). Among environmental
risk factors of HCC other than HBV, cigarette smoking is the most
prevalent in the general population in Taiwan. However, the
relative risk of HCC associated with cigarette smoking is low in
the absence of chronic HBV or HCV infection (Chen et al, 1991;
Yu et al, 1991). While there is convincing epidemiological
evidence and widespread awareness of the role of cigarette smoke
as a cause for cancer of the lung, upper aerodigestive tract and
bladder (International Agency for Research on Cancer, 1986;
Spitz et al, 1989; Talaska et al, 1991; Nakachi et al, 1993; Wynder
and Hoffmann, 1994; Muscat et al, 1996), the root mechanism
responsible for the action of cigarette smoking in hepatocarcino-
genesis is not yet well understood.
Carcinogenic compounds in cigarette smoke which have been
extensively reviewed include polycyclic aromatic hydrocarbons
(PAHs), N-nitrosamines and aromatic amines (International
Agency for Research on Cancer, 1986). The organospecificity of
these tobacco-related carcinogens for the liver in humans is
unknown. Most genotoxic chemical carcinogens are not intrinsi-
cally reactive but require metabolic conversion to DNA-binding
intermediates (Guengerich and Shimada, 1991). Our recent study
showing a significant association between genetic polymorphism
in cytochrome P450 (CYP) 2E1, a critical enzyme in the metabolic
activation of various low-molecular-weight procarcinogens,
including tobacco-specific N-nitrosamines, and HCC among ciga-
rette smokers suggests that N-nitrosamines may be involved in the
aetiology of HCC (Yu et al, 1995a). Activated metabolites of
carcinogens are subjected to metabolic conjugation and other
kinds of detoxification. N-acetyltransferase 2 is a non-inducible
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different mechanisms for increasing susceptibility to smoking-related HCC.
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liver enzyme that deactivates carcinogenic aromatic amines via
N-acetylation (Hein et al, 1993). Slow acetylators expressing little
or no N-acetyltransferase 2 enzyme activity are at increased risk of
HCC (Agundez et al, 1996).
None of the PAHs consistently found in cigarette smoke have
been shown to be hepatocarcinogens in laboratory animals. No
studies have been carried out to investigate the association
between PAHs and HCC in humans. CYP1A1 is involved in the
biotransformation of tobacco-derived PAHs such as
benzo(a)pyrene (B(a)P) into reactive diol epoxide metabolites
which can form covalent adducts with DNA (Shimada et al, 1992).
Activated metabolites of B(a)P are subjected in part to metabolic
detoxification by glutathione S-transferase M1 (GSTM1)
(Mannervik and Danielson, 1988). The metabolic balance between
activation and detoxification determines the biologically effective
dose of carcinogens, thereby substantially influencing cancer risk.
Two separate point mutations in the CYP1A1 gene have been
reported: one within exon 7 that causes an isoleucine to valine
substitution in the haem-binding region (Ile-Val polymorphism),
and the other in the 3¢ non-coding region (MspI polymorphism).
The two polymorphisms are more frequent in Japanese than in
Caucasians (Nakachi et al, 1993; Sivaraman et al, 1994). Cigarette
smoking Japanese homozygous for the variant genotype of the
MspI or Ile-Val polymorphisms who also had GSTM1 gene dele-
tion, were found to be at remarkably high risk of lung cancer
(Nakachi et al, 1993).
CYP1A1 was generally considered to be involved in extra-
hepatic carcinogenesis because early studies showed that the
expression of CYP1A1 was low in human liver (Guengerich et al,
1991). However, recent studies using more sensitive techniques
for the detection of CYP1A1 messenger RNA have demonstrated
that CYP1A1 is expressed in a high proportion of human liver
tissues (McKinnon et al, 1991; Schweikl et al, 1993). The role of
CYP1A1 genetic polymorphism in susceptibility to HCC has not
yet been investigated. This case-control study was conducted
within a large-scale cohort of men in Taiwan to test the relation-
ship between susceptibility to smoking-related HCC and genetic
polymorphisms in CYP1A1. The gene–gene interaction between
CYP1A1 and GSTM1 in the development of smoking-related
HCC was also investigated.
SUBJECTS AND METHODS
A cohort of 4841 male chronic carriers of HBV surface antigen
(HBsAg) and 2501 non-carriers aged 30–65 years who were free
of HCC was recruited from the Government Employee Central
Clinics and the Liver Unit of Chang-Gung Memorial Hospital in
Taiwan from August 1988 to June 1992. At recruitment, each
study subject was personally interviewed to obtain information on
sociodemographic characteristics (e.g. age and ethnicity), habits of
smoking and alcohol drinking, dietary consumption, as well as a
history of major chronic diseases. Each study subject was asked
about the ethnicity of both parents. Data on chronic liver disease,
including chronic hepatitis and liver cirrhosis, diagnosed by physi-
cians were thus obtained. The diagnosis of chronic hepatitis in
Taiwan was mainly based on sustained elevated serum amino-
transferase levels for ³ 6 months. Only a small fraction of the
patients with chronic hepatitis were diagnosed histologically.
Liver cirrhosis was diagnosed by clinical manifestation (including
coagulopathy, hypoalbuminemia, abnormal liver function tests,
haematologic evidence of hypersplenism, ascites, jaundice and
portal hypertension with or without variceal bleeding), histolog-
ical findings of liver biopsy and/or ultrasonography. Questionnaire
interview was carried out by well-trained research assistants.
Blood specimens, including serum and white blood cells, from the
study subjects were also obtained and frozen at –70°C until subse-
quent analysis. All study subjects gave verbal or written informed
consent for both the interview and blood collection.
Follow-up of the study subjects was performed through various
channels: annual a-fetoprotein measurement and ultrasonography
examination, personal telephone interview, and data linkage with
computer files of national death certification and cancer registry
systems. The diagnosis of HCC was based on (1) positive findings
on cytological or pathological examination and/or (2) positive
images on angiogram, ultrasonography and/or computed tomog-
raphy, combined with an a-fetoprotein level ³ 400 ng/ml. There
were 92 incident cases of HCC identified during the follow-up
period from August 1988 to June 1997. A total of 624 controls
were randomly selected from cohort subjects who were not
affected with HCC through the follow-up period. They were
matched with cases on age (± 5 years), date of blood collection and
questionnaire interview (± 3 months). Successful genotyping was
obtained for 84 of the 92 case subjects and 563 (154 HBsAg-nega-
tive and 409 HBsAg-positive) of the 624 control subjects. Ninety-
six percent (81/84) of the HCC cases with available data on
CYP1A1 and GSTM1 genotypes were positive for HBsAg.
Genomic DNAs were isolated from peripheral leucocytes. For
analysis of the MspI restriction fragment length polymorphism
in CYP1A1 the following two primers were used: 5¢-
TAGGAGTCTTGTCTCATGCCT-3¢ and 5¢-CAGTGAAGAGGT-
GTAGCCGCT-3¢ (Nakachi et al, 1993). Amplification was
performed using initial denaturation at 94°C for 5 min followed by
30 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 1 min, with
a final extension at 72°C for 5 min. This generated a 340 bp
fragment that was then subjected to digestion with MspI (New
England Biolabs, Beverly, MA, USA) according to the manufac-
turer’s instruction. The digested product was visualized on a 2%
agarose gel, followed by ethidium bromide staining. The presence
of the variant allele (m2) was indicated by bands of 200- and
140-bp, whereas no digestion of the wild-type allele (m1)
occurred. A modified method, originally described by Oyama and
co-workers, was used to identify the other CYP1A1 polymor-
phism resulting in the substitution of isoleucine for valine at
residue 462 in the haem-binding region (Oyama et al, 1995).
Genomic DNA was amplified by polymerase chain reaction (PCR)
using the primers 5¢-GAACTGCCACTTCAGCTGTCT-3¢ and
5¢-GAAAGACCTCCCAGCGGTCA-3¢. The amplification reac-
tion was at 94°C for 5 min to effect initial denaturation, followed
by 30 cycles of 20 s at 94°C, 20 s at 55°C, and 40 s at 72°C, with a
final extension at 72°C for 5 min. Following amplification, PCR
products were digested with HincII (New England Biolabs,
Beverly, MA, USA) at 37°C for 3 h. The digested products were
electrophoresed on a 3% agarose gel and visualized by ethidium
bromide staining. PCR products of Val polymorphism can be cut
between codon 462 (GTT) and codon 463 (GAC) by HincII. The
GSTM1 genotyping for gene deletion was carried out by PCR
amplification with primers for exons 6 and 7 (Chen et al, 1996).
All assays were conducted and interpreted blindly to case-control
status.
The differences in the allele frequencies of the CYP1A1 gene
between HBsAg carriers and non-carriers were tested by multiple
linear regression with simultaneous control for ethnic groups and600 M-W Yu et al
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age. Odds ratio (OR) and confidence interval (CI) were calculated
by unconditional logistic regression and adjusted for potential
confounding factors. All P-values were calculated from two-sided
statistical tests.
RESULTS
Distributions of CYP1A1 polymorphisms in HBsAg-
positive and HBsAg-negative controls
Ninety-eight percent of the study subjects reported that their father
and mother had the same ethnic group. Table 1 shows the distribu-
tion of the CYP1A1 genetic polymorphisms in HBsAg-positive
and HBsAg-negative control subjects by ethnic group. The
ethnicity distribution presented was based on fathers’ ethnic
groups of the study subjects. The MspI variant allele (m2) was less
frequent in HBsAg-positive controls than in HBsAg-negative
controls, irrespective of ethnic group. Since the Ile-Val poly-
morphism is closely linked to the MspI polymorphism (Nakachi
et al, 1993), the Ile-Val variant allele (Val) was also reduced in
frequency among HBsAg carriers in each ethnic group. The
overall frequencies of the MspI (P = 0.0377) and Ile-Val
(P = 0.0381) variant alleles were significantly lower in HBsAg
carriers than in non-carriers after adjustment for ethnic group and
age. Since only three HCC cases with available data on CYP1A1
and GSTM1 genotypes were HBsAg-negative, the only way to
control for the effect of HBsAg carrier status in stratified analyses
was to restrict the analyses to chronic HBV carriers. The following
analyses of CYP1A1 polymorphisms and HCC risk were thus
carried out among chronic HBV carriers.
CYP1A1 polymorphisms and HCC risk in chronic HBV
carriers
The mean ± standard deviation (s.d.) of ages for the 81 HBsAg-
positive HCC cases and 409 HBsAg-positive control subjects in
the nested case-control study on CYP1A1 polymorphisms and
HCC were 53.1 ± 9.4 and 51.9 ± 9.4 years respectively. Table 2
shows the frequencies of CYP1A1 genotypic variants among
HBsAg-positive HCC cases and controls. The MspI allele
frequency for the m2 variant type was 43.2% in cases and 39.2%
in controls. The corresponding figures for the Ile-Val variant allele
were 25.3% and 23.2% respectively. Both MspI and Ile-Val alleles
were found to be in Hardy–Weinberg equilibrium. There were no
statistically significant differences in the distributions of CYP1A1
polymorphisms between cases and controls.
Interaction between cigarette smoking and CYP1A1
polymorphism in HCC
After stratifying by status of cigarette smoking, we further exam-
ined the associations between CYP1A1 polymorphisms and HCC
risk among chronic HBV carriers (Table 3). Among non-smokers,
there were essentially no differences in the distributions of
CYP1A1 polymorphisms between cases and controls. Conversely,
among smokers, the presence of the MspI variant allele signifi-
cantly increased HCC risk, showing a multivariate-adjusted OR of
3.15 (95% CI 1.20–8.28; P = 0.0196). Cigarette smokers with the
Ile-Val variant allele were also at increased risk of HCC (adjusted
Table 1 Variant CYP1A1 allele frequencies in controls by HBsAg status
and ethnic group
Marker (variant allele) Total
HBsAg chromosomes
Ethnic group status MspI (m2) Ile-Val (Val) tested
%%
Fukien Taiwanese Negative 43.2 28.8 132
Positive 39.8 23.0 470
Hakka Taiwanese Negative 52.6 36.8 38
Positive 39.4 22.3 94
Mainland Chinese Negative 47.1 27.5 138
Positive 38.2 24.0 254
Table 2 Frequency distributions of CYP1A1 genotypes in HBsAg-positive
HCC cases and controls
Cases Controls
Adjusteda
Genotypes No. (%) No. (%) odds ratio (95% CI)
MspI polymorphism
m1/m1 25 (30.9) 152 (37.2) 1.0
m1/m2 42 (51.8) 193 (47.2) 1.41 (0.81–2.46)
m2/m2 14 (17.3) 64 (15.6) 1.47 (0.71–3.08)
Ile-Val polymorphism
Ile/Ile 46 (56.8) 239 (58.4) 1.0
Ile/Val 29 (35.8) 150 (36.7) 1.02 (0.60–1.73)
Val/Val 6 (7.4) 20 (4.9) 1.61 (0.59–4.38)
aAdjusted for effects of age, cigarette smoking, alcohol drinking, ethnic
groups and chronic liver disease
Table 3 CYP1A1 genetic polymorphisms and HCC risk in HBsAg carriers by status of cigarette smoking
Non-smokers Smokers
Genotype Cases Controls ORa (95% CI) Cases Controls OR (95% CI)
MspI polymorphism
m1/m1 19 86 1.0 6 66 1.0
m1/m2 and m2/m2 29 158 0.92 (0.47–1.78) 27 99 3.15 (1.20–8.28)b
Ile-Val polymorphism
Ile/Ile 33 147 1.0 13 92 1.0
Ile/Val and Val/Val 15 97 0.74 (0.37–1.46) 20 73 1.99 (0.91–4.37)c
a Adjusted for age, alcohol drinking, ethnic groups and chronic liver disease. b P = 0.0196. c P = 0.0855.Genotypes of CYP1A1 and HCC risk 601
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OR 1.99, 95% CI 0.91–4.37) compared with those without the
allele; this association was marginally significant (P = 0.0855).
No significant association between cumulative exposure to
cigarette smoke and HCC was observed when the association was
examined in strata of CYP1A1 genotypes. Because activated
metabolites of tobacco-derived PAHs are subjected in part to meta-
bolic detoxification by GSTM1 (Mannervik and Danielson, 1988),
the association between pack-years of cigarette smoking and HCC
was assessed in categories simultaneously stratified by genotypes
of CYP1A1 and GSTM1 (Table 4). Genetic data for GSTM1 were
available for all the 81 HBsAg-positive HCC cases and 407
HBsAg-positive controls. Fifty-one percent of the cases and 55%
of the controls were the homozygotes for the GSTM1-null geno-
type which express no protein. After adjusting for potential
confounders, the effect of smoking was observed to be most
pronounced in those with at least one MspI (OR [95% CI] for
smokers of ≤16.3 and > 16.3 pack-years vs non-smokers, 3.34
[1.16–9.65] and 1.54 [0.48–4.97] respectively) or Ile-Val variant
allele (OR [95% CI] for smokers of ≤ 16.3 and > 16.3 pack-years
vs non-smokers, 9.04 [1.92–42.67] and 4.71 [0.94–23.69] respec-
tively) of CYP1A1 combined with a deficient genotype of
GSTM1; however, a monotonic dose–response relation was not
observed.
The MspI and Ile-Val variant alleles of CYP1A1 are in linkage
disequilibrium (Nakachi et al, 1993). It is likely that the effect of
the MspI polymorphism is essentially ascribed to the Ile-Val
polymorphism which was associated with gene inducibility and
enzymatic activity (Kawajiri et al, 1993; Crofts et al, 1994). This
hypothesis was examined in Table 5. Among smoking chronic
HBV carriers homozygous for the wild-type allele of the Ile-Val
polymorphism, the presence of the MspI variant allele still
increased HCC risk. Adjustment for age, alcohol drinking, ethnic
groups and chronic liver disease did not materially change the
results. This suggests that MspI and Ile-Val polymorphisms
may have different mechanisms for increasing susceptibility to
smoking-related HCC.
DISCUSSION
Our previous case-control study found an excess risk of HCC in
first-degree relatives of HCC patients, even after adjustment for
chronic HBV carrier status (Chen et al, 1991). Segregation
analysis of familial HCC demonstrated an interaction between
HBV infection and a major genetic locus (Shen et al, 1991). These
epidemiological findings suggest that inherited predisposition may
be a component of HCC risk. While the relationships between
environmental risk factors and HCC have been actively studied,
the understanding of the genetic basis of HCC remains primitive.
Both viral and chemical carcinogens are involved in the human
hepatocarcinogenesis. Previous epidemiological studies have
demonstrated that aflatoxin exposure and cigarette smoking are
important risk factors for HCC (Tsukuma et al, 1990; Chen et al,
1991, 1996; Yu et al, 1991; Yu et al, 1997). Aflatoxins and most
genotoxic chemical carcinogens in tobacco smoke are not intrinsi-
cally reactive but require metabolic conversion to DNA-binding
intermediates (Guengerich and Shimada, 1991). While CYP1A2 is
the P450 enzyme principally responsible for the bioactivation of
aflatoxin B1 at low substrate concentrations associated with dietary
Table 4 Adjusted odds ratiosa of HCC associated with cumulative exposure to cigarette smoke in HBsAg carriers by combined genotypes of
CYP1A1 and GSTM1
Pack-years of smoking
No. of No. of
CYP1A1 GSTM1 cases controlsb ≤ 16.3 vs 0 > 16.3 vs 0
m1/m1 Non-null 12 73 0.46 (0.05–4.28) 0.59 (0.11–3.33)
m1/m1 Null 13 77 0.29 (0.03–2.47) 0.66 (0.10–4.53)
m1/m2 and m2/m2 Non-null 28 109 0.71 (0.20–2.51) 1.52 (0.51–4.54)
m1/m2 and m2/m2 Null 28 147 3.34 (1.16–9.65)c 1.54 (0.48–4.97)
Ile/Ile Non-null 24 113 0.52 (0.10–2.59) 0.81 (0.25–2.64)
Ile/Ile Null 22 124 0.63 (0.16–2.42) 0.48 (0.11–2.19)
Ile/Val and Val/Val Non-null 16 69 0.90 (0.20–4.16) 1.45 (0.36–5.83)
Ile/Val and Val/Val Null 19 100 9.04 (1.92–42.67)d 4.71 (0.94–23.69)e
a Adjusted for effects of age, alcohol drinking, and chronic liver disease. b One control had no available data on quantity of smoking per day
and two controls had no available data on GSTM1 genotype. c P = 0.0259. d P = 0.0054. e P = 0.0601.
Table 5 HCC risk associated with CYP1A1 MspI polymorphism in HBsAg carriers homozygous for the Ile/Ile genotype of the CYP1A1 Ile-
Val polymorphism
Non-smokers Smokers
Genotype Cases Controls OR (95% CI) Cases Controls OR (95% CI)
m1/m1 19 85 1.0 6 64 1.0
m1/m2 13 57 1.02 (0.47–2.23) 5 26 2.05 (0.58–7.32)
m2/m2 1 5 0.89 (0.10–8.11) 2 2 10.67 (1.27–89.86)a
a P = 0.0295. 602 M-W Yu et al
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exposure (Gallagher et al, 1994), CYP1A1 is involved in the meta-
bolic activation of B(a)P and other PAH constituents of cigarette
smoke (Shimada et al, 1992). Polymorphisms associated with
enzymatic activity of CYP1A1 may determine susceptibility to
smoking-related cancer. The frequencies of the CYP1A1 MspI and
Ile-Val variant alleles among Chinese in Taiwan are similar to
those described for Japanese, but much higher than those in
Caucasians (Nakachi et al, 1993; Sivaraman et al, 1994). In this
case-control study nested within a prospective study, we found that
the relationship between CYP1A1 polymorphisms and HCC in
chronic HBV carriers depended on the status of cigarette smoking.
The CYP1A1 MspI polymorphism was significantly related to
HCC risk in cigarette smokers, whereas no significant association
was evident for those who had never smoked. Because the Val
allele of the Ile-Val polymorphism is much less frequent than the
m2 allele of the MspI polymorphism and the limited sample size,
the increased risk of HCC associated with the presence of the Val
allele in smokers only reached the borderline significance level.
Electrophilic metabolites of B(a)P and other PAHs activated by
CYP1A1 are subjected, in part, to metabolic detoxification by
GSTM1 (Mannervik and Danielson, 1988). Perhaps individuals
with GSTM1 non-null genotypes in combination with the high-
risk gene of CYP1A1 are able to eliminate the activated metabo-
lites of PAHs rapidly and efficiently, and thus tolerate carcinogenic
insults. The HCC risk associated with cumulative exposure to
cigarette smoke in this study was found to be most pronounced
among chronic HBV carriers with at least one variant allele of the
CYP1A1 MspI, or Ile-Val polymorphism, who also had homozy-
gous deletion of the GSTM1 gene. These results are compatible
with the hypothesis that CYP1A1 polymorphism is an important
modulator of the hepatocarcinogenic effect of cigarette smoke
among chronic HBV carriers. They also indirectly support a role
for PAHs in cigarette smoke that are activated by CYP1A1 in the
aetiology of HCC. The frequency of the GSTM1-null genotype is
high in human populations, approximately 50%, with a reported
range of 30–70% (Rebbeck, 1997). Intervention aimed at reducing
cigarette smoking may be important for the prevention of HCC in
areas where chronic HBV infection and the high-risk gene of
CYP1A1 are common.
The frequencies of many polymorphic genetic markers vary
markedly between different populations. One major difficulty that
often arises in case-control studies of genetic markers and disease
is the choice of an appropriate control group for a sample of cases
drawn from a mixed population consisting of different subgroups
with diverse distributions of genetic markers. Taiwan is an
endemic area of HBV infection with a HBsAg carrier rate of
15–20%. Chronic HBV infection has been demonstrated as the
most important determinant of HCC in Taiwan (Beasley, 1988;
Chen et al, 1991; Yu et al, 1991; Yu and Chen, 1994). In this study,
the CYP1A1 MspI and Ile-Val variant alleles were observed to be
less prevalent in HBsAg carriers than in non-carriers. This gene
frequency difference was present in each ethnic group and was
statistically significant after adjustment for ethnic groups and age
when all the three ethnic groups were pooled in the analysis. Since
only three HCC cases were negative for HBsAg in this study, we
thus restricted the analyses of CYP1A1 polymorphisms and HCC
to chronic HBV carriers. Although the mechanism responsible for
the discrepancies in the allelic frequencies of CYP1A1 polymor-
phisms between HBsAg carriers and non-carriers is unclear, this
study raises the possibility that the failure to take into account
HBsAg carrier status in analysis of genetic markers and HCC may
cause biased estimates of association, especially in endemic areas
of HBV infection.
The Ile-Val polymorphism of the CYP1A1 gene results in the
replacement of Ile by Val at amino acid residue 462 in the haem-
binding region. The Val variant allele was shown to be associated
with increased gene inducibility and catalytic activity (Kawajiri
et al, 1993; Crofts et al, 1994). The MspI polymorphism is located
in the 3¢ non-coding region of the CYP1A1 gene. Although the
MspI polymorphism has been shown to co-segregate with the
inducibility phenotype of the CYP1A1 enzyme in a family study,
the mechanism for this association remains to be established
(Petersen et al, 1991). Since the MspI and Ile-Val variant alleles of
CYP1A1 are in linkage disequilibrium (Nakachi et al, 1993), it is
likely that the association between the MspI polymorphism and
HCC among cigarette smokers observed in this study is essentially
ascribed to the Ile-Val polymorphism. In smoking chronic HBV
carriers homozygous for the wild-type genotype of the Ile-Val
polymorphism, however, we found that the MspI variant allele was
still associated with increased risk of HCC. This finding suggests
that the MspI and Ile-Val polymorphisms may be acting through
different mechanisms for influencing susceptibility to smoking-
related HCC.
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